Pharmacokinetics: After ocular administration of a 0.2% solution, plasma concentrations peaked within 1 to 4 hours and declined with a systemic half-life of approximately 3 hours.
In humans, systemic metabolism of brimonidine is extensive.
It is metabolized primarily by the liver.
Urinary excretion is the major route of elimination of the drug and its metabolites.Approximately 87% of an orally-administered radioactive dose was eliminated within 120 hours, with 74% found in the urine.
Brimonidine tartrate ophthalmic solution is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The IOP lowering efficacy of Brimonidine tartrate ophthalmic solution diminishes over time in some patients.This loss of effect appears with a variable time of onset in each patient and should be closely monitored.
Brimonidine tartrate ophthalmic solution is contraindicated in patients with hypersensitivity to brimonidine tartrate or any component of this medication.It is also contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy.